Osimertinib is able to increase the phosphorylation of AXL in EGFR-mutated non-small cell lung cancer (NSCLC) cells, which subsequently activate HER3, MET, EGFR and the corresponding downstream signals. This evidence concerns the gene ERBB3 and non-small cell lung carcinoma.